| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-8703(98)70327-8 |
| P698 | PubMed publication ID | 9506336 |
| P50 | author | Atsunori Fukuhara | Q59697421 |
| P2093 | author name string | T Kobayashi | |
| O Katoh | |||
| N Awata | |||
| H Tateyama | |||
| S Otsuji | |||
| M Funamoto | |||
| E Tsuchikane | |||
| S Sumitsuji | |||
| P2860 | cites work | Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty | Q70054975 |
| Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study | Q70825486 | ||
| Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells | Q71331667 | ||
| Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study | Q71571194 | ||
| Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy | Q72157073 | ||
| Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography | Q72400640 | ||
| Two major signal pathways linked | Q72648463 | ||
| Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator | Q72963259 | ||
| A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group | Q28245560 | ||
| A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators | Q28245573 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Inhibition of the EGF-Activated MAP Kinase Signaling Pathway by Adenosine 3′,5′-Monophosphate | Q30464735 | ||
| Restenosis after coronary angioplasty: an overview | Q33532008 | ||
| Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months | Q34563209 | ||
| Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study | Q36837907 | ||
| Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia | Q38253045 | ||
| Platelet-derived growth factor | Q38350498 | ||
| Intimal hyperplasia, vascular modeling, and the restenosis problem | Q40763675 | ||
| Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells | Q41448032 | ||
| Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors | Q43475071 | ||
| Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry | Q45623159 | ||
| Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture | Q67466758 | ||
| Arterial injury and the enigma of coronary restenosis | Q67733226 | ||
| Clinical trials of restenosis after coronary angioplasty | Q67962771 | ||
| Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF | Q68252685 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 495-502 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | American Heart Journal | Q2227156 |
| P1476 | title | Impact of cilostazol on intimal proliferation after directional coronary atherectomy | |
| P478 | volume | 135 |
| Q47134539 | Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease |
| Q46130708 | Cilostazol suppresses neointimal hyperplasia in canine vein grafts |
| Q28193750 | Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT) |
| Q31966638 | Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus |
| Q28184286 | Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine |
| Q34297731 | Endovascular and surgical revascularization for patients with intermittent claudication |
| Q73081818 | Final results of the STent versus directional coronary Atherectomy Randomized Trial (START) |
| Q73200679 | Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction |
| Q34105472 | Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential |
| Q34680320 | Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. |
| Q34070572 | Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family |
| Q41939506 | Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model |
| Q36405138 | The vascular effects of cilostazol |
Search more.